<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical features of osteogenesis imperfecta (OI) by type</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical features of osteogenesis imperfecta (OI) by type</h1>
<div class="graphic"><div class="figure"><div class="ttl">Clinical features of osteogenesis imperfecta (OI) by type</div><div class="cntnt"><table cellspacing="0"><colgroup span="10" width="10%"></colgroup> <tbody> <tr> <td class="subtitle1">Type<br/> (MIM#)</td> <td class="subtitle1">Inheritance</td> <td class="subtitle1">Gene/protein</td> <td class="subtitle1">Severity</td> <td class="subtitle1">Fractures</td> <td class="subtitle1">Stature</td> <td class="subtitle1">DI</td> <td class="subtitle1">Sclerae</td> <td class="subtitle1">Hearing loss</td> <td class="subtitle1">Other</td> </tr> <tr> <td class="subtitle2_left" colspan="10">Defects in collagen synthesis, structure, and assembly</td> </tr> <tr> <td class="indent1">I<br/> (#166200)<sup>[1]</sup></td> <td>AD</td> <td><em>COL1A1</em> (type 1 collagen [alpha 1])</td> <td>Mild</td> <td>Few to 100</td> <td>Normal height or mild short stature</td> <td>Rare</td> <td>Blue</td> <td>Present in approximately 50%</td> <td>70 to 75% of OI is type I</td> </tr> <tr> <td class="indent1" rowspan="2">II<br/> (IIA – #166210, IIB – #610854)</td> <td>AD (new mutations or parental mosaicism)</td> <td><em>COL1A1</em>, <em>COL1A2</em> (type 1 collagen [alpha 1 and 2])</td> <td rowspan="2">Perinatal lethal</td> <td rowspan="2">Multiple at birth</td> <td rowspan="2">Severely short stature</td> <td rowspan="2">Yes</td> <td rowspan="2">Dark blue/gray</td> <td rowspan="2">–</td> <td rowspan="2">–</td> </tr> <tr> <td>AR</td> <td><em>CRTAP</em>, <em>P3H1</em> (cartilage-associated protein/prolyl 3-hydroxylase 1)</td> </tr> <tr> <td class="indent1" rowspan="2">III<br/> (#259420)</td> <td>AD</td> <td><em>COL1A1</em>, <em>COL1A2</em> (type 1 collagen [alpha 1 and 2])</td> <td rowspan="2">Severe</td> <td rowspan="2">Multiple at birth</td> <td rowspan="2">Very short stature</td> <td rowspan="2">Yes</td> <td rowspan="2">Grayish</td> <td rowspan="2">Frequent</td> <td rowspan="2">–</td> </tr> <tr> <td>AR</td> <td><em>CRTAP</em>, <em>LEPRE1</em>, <em>PP1B</em> (cartilage-associated protein/prolyl 3-hydroxylase 1/cyclophilin B)</td> </tr> <tr> <td class="indent1">IV<br/> (#166220)<sup>[2]</sup></td> <td>AD</td> <td><em>COL1A1</em>, <em>COL1A2</em> (type 1 collagen [alpha 1 and 2])</td> <td>Mild to moderate</td> <td>Multiple in neonatal period or infancy</td> <td>Moderate short stature</td> <td>Some patients</td> <td>Grayish</td> <td>Reported in some</td> <td>–</td> </tr> <tr> <td class="subtitle2_left" colspan="10">Histologically distinct defects in bone mineralization</td> </tr> <tr> <td class="indent1">V<br/> (#610967)<sup>[3-6]</sup></td> <td>AD</td> <td><em>IFITM5</em> (bone-restricted IFITM-like)</td> <td>Moderate to severe</td> <td>Multiple</td> <td>Moderate short stature</td> <td>No</td> <td>White</td> <td>No</td> <td>–</td> </tr> <tr> <td class="indent1">VI<br/> (#613982)<sup>[7-9]</sup></td> <td>AR</td> <td><em>SERPINF1</em> (pigment epithelium-derived factor)</td> <td>Moderate to severe</td> <td>Multiple between 6 and 18 months of age</td> <td>Mild short stature</td> <td>No</td> <td>White</td> <td>No</td> <td>–</td> </tr> <tr> <td class="subtitle2_left" colspan="10">Collagen-folding protein abnormalities in prolyl-3-hydroxylation complex<sup>[10-13]</sup></td> </tr> <tr> <td class="indent1">VII<br/> (#610682)</td> <td>AR</td> <td><em>CRTAP</em> (cartilage-associated protein)</td> <td>Moderate</td> <td>Multiple</td> <td>Mild short stature</td> <td>No</td> <td>White</td> <td>No</td> <td>–</td> </tr> <tr> <td class="indent1">VIII<br/> (#610915)</td> <td>AR</td> <td><em>P3H1</em> (prolyl 3-hydroxylase 1)</td> <td>Lethal or severe</td> <td>Multiple</td> <td>Short-limbed dwarfism</td> <td>No</td> <td>White</td> <td>Not reported</td> <td>–</td> </tr> <tr> <td class="indent1">IX<br/> (#259440)</td> <td>AR</td> <td><em>PP1B</em> (cyclophilin B)</td> <td>Lethal or severe</td> <td>Multiple</td> <td>Short-limbed dwarfism</td> <td>Yes</td> <td>Blue</td> <td>No</td> <td>–</td> </tr> <tr> <td class="subtitle2_left" colspan="10">Collagen-processing and cross-linking defects<sup>[14,15]</sup></td> </tr> <tr> <td class="indent1">X<br/> (#613848)</td> <td>AR</td> <td><em>SERPINH1</em> (heat shock protein 47)</td> <td>Lethal or severe</td> <td>Multiple</td> <td>Severe short stature</td> <td>Yes</td> <td>Blue at birth</td> <td>Not reported</td> <td>–</td> </tr> <tr> <td class="indent1">XI<br/> (#610968)<sup>[16,17]</sup></td> <td>AR</td> <td><em>FKBP10</em> (FK506-binding protein 65)</td> <td>Severe</td> <td>Multiple</td> <td>Severe short stature</td> <td>No</td> <td>Gray/white</td> <td>Not reported</td> <td>Pathogenic variants in <em>FKBP10</em> also cause Bruck syndrome type 1</td> </tr> <tr> <td class="indent1">XII<br/> (#613849)<sup>[18]</sup></td> <td>AR</td> <td><em>BMP1</em> (bone morphogenetic protein 1)</td> <td>Moderate to severe</td> <td>Multiple</td> <td>Short stature</td> <td>No</td> <td>White</td> <td>Reported in some</td> <td>Can have osteopenia or bone fragility</td> </tr> <tr> <td class="subtitle2_left" colspan="10">Osteoblast lineage abnormality</td> </tr> <tr> <td class="indent1">XIII<br/> (#614856)<sup>[19-22]</sup></td> <td>AR</td> <td><em>SP7</em> (osterix)</td> <td>Moderate to severe</td> <td>Multiple</td> <td>Short stature</td> <td>No</td> <td>White</td> <td>No</td> <td>–</td> </tr> <tr> <td class="indent1">XIV<br/> (#615066)<sup>[23-25]</sup></td> <td>AR</td> <td><em>TMEM38B</em> (trimeric intracellular cation type B)</td> <td>Moderate to severe</td> <td>Multiple</td> <td>Short stature</td> <td>No</td> <td>White to blue</td> <td>No</td> <td>Cardiovascular defects and endocrine concerns</td> </tr> <tr> <td class="indent1">XV<br/> (#615220)<sup>[26-28]</sup></td> <td>AR</td> <td><em>WNT1</em> (Wnt family member 1)</td> <td>Moderate to severe</td> <td>Multiple</td> <td>Short stature</td> <td>No</td> <td>White</td> <td>No</td> <td>Muscle hypotonia and possible neurologic defects including intellectual disability</td> </tr> <tr> <td class="indent1">XVI<br/> (#616229)<sup>[29,30]</sup></td> <td>AR</td> <td><em>CREB3L1</em> (old astrocyte specifically induced substance [OASIS])</td> <td>Severe</td> <td>Multiple</td> <td>Short stature</td> <td>No</td> <td>White to blue</td> <td>Reported in some</td> <td>Antenatal presentation</td> </tr> <tr> <td class="indent1">XVII<br/> (#616507)<sup>[31,32]</sup></td> <td>AR</td> <td><em>SPARC</em> (osteonectin)</td> <td>Severe</td> <td>Multiple</td> <td>Severe short stature</td> <td>Yes</td> <td>White/gray</td> <td>Yes</td> <td>May present initially as significant neuromuscular weakness with fractures</td> </tr> <tr> <td class="subtitle2_left" colspan="10">Newer forms of OI</td> </tr> <tr> <td class="indent1">XVIII<br/> (#617952)<sup>[33]</sup></td> <td>AR</td> <td><em>TENT5A</em> (family with sequence similarity 46 member A)</td> <td>Severe</td> <td>Multiple</td> <td>Severe short stature</td> <td>Yes</td> <td>Blue/bluish gray</td> <td>Yes</td> <td> <p>Developmental and speech delays and autonomic nervous system dysfunction</p> Overlap with Stuve-Wiedemann syndrome </td> </tr> <tr> <td class="indent1">XIX<br/> (#301014)<sup>[34]</sup></td> <td>XLR</td> <td><em>MBTPS2</em> (site 2 protease)</td> <td>Severe</td> <td>Multiple</td> <td>Severe short stature</td> <td>No</td> <td>Blue</td> <td>Yes</td> <td>Elevated urinary pyridinoline cross-links</td> </tr> <tr> <td class="indent1">XX<br/> (#618644)<sup>[35]</sup></td> <td>AR</td> <td><em>MESD</em> (mesoderm development LRP chaperone)</td> <td>Lethal in the early neonatal period or severe</td> <td>Multiple</td> <td>Severe short stature</td> <td>Yes</td> <td>Blue</td> <td>Reported in 1 individual</td> <td> <p>Can include developmental delay/intellectual disability</p> Several patients died from respiratory failure </td> </tr> <tr> <td class="indent1">XXI<br/> (#609024)<sup>[36]</sup></td> <td>AR</td> <td><em>KDELR2</em> (KDEL endoplasmic reticulum protein retention receptor 2)</td> <td>Moderate to severe</td> <td>Multiple</td> <td>Short stature</td> <td>Yes</td> <td>Blue/bluish gray</td> <td>Yes</td> <td>Low bone mass</td> </tr> <tr> <td class="indent1">XXII<br/> (#619795)<sup>[37]</sup></td> <td>AR</td> <td><em>CCDC134</em> (coiled-coin domain-containing protein 134)</td> <td>Moderate to severe or lethal in the neonatal period</td> <td>Multiple</td> <td>Short stature</td> <td>Yes</td> <td>White to gray (variable)</td> <td>Reported in 1 individual</td> <td>Antenatal presentation</td> </tr> </tbody></table></div><div class="graphic_lgnd">Seventy to 75% of OI is type I; the other forms are rare. Radiographic findings of OI are covered separately (refer to companion UpToDate table of radiographic findings).</div><div class="graphic_footnotes">DI: dentinogenesis imperfecta; AD: autosomal dominant; AR: autosomal recessive; <em>LEPRE1</em>: leucine- and proline-enriched proteoglycan 1; <em>PPIB</em>: peptidyl-prolyl isomerase B; <em>IFITM5</em>: interferon-induced transmembrane protein 5; <em>SERPINF1</em>: serpin peptidase inhibitor, clade F, member 1; <em>SERPINH1</em>: serpin peptidase inhibitor, clade H, member 1; <em>FKBP10</em>: FK506-binding protein 10; <em>SP7</em>: Sp7 transcription factor; <em>TMEM38B</em>: transmembrane protein 38B; <em>CREB3L1</em>: cAMP-responsive element-binding protein 3-like 1; <em>SPARC</em>: secreted protein acidic and cysteine rich; <em>TENT5A</em>: terminal nucleotidyltransferase 5A; XLR: X-linked recessive; <em>MBTPS2</em>: membrane-bound transcription factor peptidase, site 2.</div><div class="graphic_reference">References:
<ol>
<li>Maioli M, Gnoli M, Boarini M, et al. Genotype-phenotype correlation study in 364 osteogenesis imperfecta Italian patients. Eur J Hum Genet 2019; 27:1090.</li>
<li>Byers PH, Wallis GA, Willing MC. Osteogenesis imperfecta: Translation of mutation to phenotype. J Med Genet 1991; 28:433.</li>
<li>Balasubramanian M, Parker MJ, Dalton A, et al. Genotype-phenotype study in type V osteogenesis imperfecta. Clin Dysmorphol 2013; 22:93.</li>
<li>Cho TJ, Lee KE, Lee SK, et al. A single recurrent mutation I the 5'-UTR of IFITM5 causes osteogenesis imperfect type V. Am J Hum Genet 2012; 91:343.</li>
<li>Semler O, Garbes L, Keupp K, et al. A mutation I the 5'UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus. Am J Hum Genet 2012; 91:349.</li>
<li>Hanagata N, Li X, Morita H, et al. Characterization of the osteoblast-specific transmembrane protein IFITM5 and analysis of IFITM5-deficienc mice. J Bone Miner Metab 2011; 29:279.</li>
<li>Becker J, Semler O, Gilissen C, et al. Exome sequencing identifies truncating mutation in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am J Hum Genet 2011; 88:362.</li>
<li>Hoyer-Kuhn H, Semler O, Garbes L, et al. A nonclassical IFITM5 mutation located in the coding region causes severe osteogenesis imperfecta with prenatal onset. J Bone Miner Res 2014; 29:1387.</li>
<li>Farber CR, Reich A, Barnes AM, et al. A novel IFITM5 mutation in severe atypical osteogenesis imperfecta type VI impairs osteoblast production of pigment epithelium-derived factor. J Bone Miner Res 2014; 29:1402.</li>
<li>Morello R, Bertin TK, Chen Y, et al. CRTAP is required for prolyl 3-hydoxylation and mutations cause recessive osteogenesis imperfecta. Cell 2006; 127:291.</li>
<li>Barnes AM, Chang W, Morello R, et al. Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. N Engl Med 2006; 355:2757.</li>
<li>Cabral WA, Chang W, Barnes AM, et al. Prolyl 3-hyroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfect. Nat Genet 2007; 39:359.</li>
<li>Marini JC, Cabral WA, Barnes AM, Chang W. Components of the collagen prolyl 3-hydroxylation complex are crucial for normal bone development. Cell Cycle 2009; 6:1675.</li>
<li>Christiansen HE, Schwarze U, Pyott SM et al. Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta. Am J Hum Genet 2019; 86:389.</li>
<li>Marshall C, Lopez J, Crookes L, et al. A novel homozygous variant in SERPINH1 associated with a severe, lethal presentation of osteogenesis imperfecta with hydranencephaly. Gene 2016; 595:49.</li>
<li>Alanay Y, Avayan H, Camacho N, et al. Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta. Am J Hum Genet 2010; 86:551.</li>
<li>Duran I, Nevarez L, Sarukhanov A, et al. HSP47 and FKBPP65 cooperate in the synthesis of type I procollagen. Hum Mol Genet 2015; 24:1918.</li>
<li>Lapunzina P, Alan M, Temtamy S, et al. Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta. Am J Hum Genet 2010; 87:110.</li>
<li>Martínez-Glez V, Valencia M, Caparrós-Martín JA, et al. Identification of a mutation causing deficient BMP1/mTLD proteolytic activity in autosomal recessive osteogenesis imperfecta. Hum Mutat 2012; 33:343.</li>
<li>Pollitt RC, Saraff V, Dalton A, et al. Phenotype variability in patients with osteogenesis imperfecta caused by BMP1 mutations. Am J Med Genet A 2016; 170:3150.</li>
<li>Asharani PV, Keupp K, Semler O, et al. Attenuated BMP1 function compromises osteogenesis, leading to bone fragility in humans and zebrafish. Am J Hum Genet 2012; 90:661.</li>
<li>Lindahl K, Barnes AM, Fratzl-Zelman N, et al. COL1 C-propeptide cleavage site mutations cause high bone mass osteogenesis imperfecta. Hum Mutat 2011; 32:598.</li>
<li>Shaheen R, Alazami AM, Alshammari MJ, et al. Study of autosomal recessive osteogenesis imperfecta in Arabia reveals a novel locus defined by TMEM38B mutation. J Med Genet 2012; 49:630.</li>
<li>Volodarsky M, Markus B, Cohen I, et al. A deletion mutation in TMEM38B associated with autosomal recessive osteogenesis imperfecta. Hum Mutat 2013; 34:582.</li>
<li>Webb EA, Balasubramanian M, Fratzl-Zelman N, et al. Phenotypic spectrum in osteogenesis imperfecta due to mutations in TMEM38B: Unraveling a complex cellular defect. J Clin Endocrinol Metab 2017; 102:2019.</li>
<li>Keupp K, Beleggia F, Kayserli H, et al. Mutations in WNT1 cause different forms of bone fragility. Am J Hum Genet 2013; 92:565.</li>
<li>Pyott SM, Tran TT, Leistritz DF, et al. WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta. Am J Hum Genet 2013; 92:590.</li>
<li>Faqeih E, Shahee R, Alkuraya FS. WNT1 mutation with recessive osteogenesis imperfecta and profound neurological phenotype. J Med Genet 2013; 50:491.</li>
<li>Symoens S, Malfait F, D'hondt S, et al. Deficiency for the ER-stress transducer OASIS causes severe recessive osteogenesis imperfecta in humans. Orphanet J Rare Dis 2013; 8:154.</li>
<li>Lindahl K, Aström E, Dragomir A, et al. Homozygosity for CREB3L1 premature stop codon in first case of recessive osteogenesis imperfecta associated with OASIS-deficiency to survive infancy. Bone 2018; 114:268.</li>
<li>Mendoza-Londono R, Fahiminiya S, Majewski J, et al. Recessive osteogenesis imperfecta caused by missense mutations in SPARC. Am J Hum Genet 2015; 96:979.</li>
<li>Durkin A, DeVile C, Arundel P, et al. Expanding the phenotype of SPARC-related osteogenesis imperfecta: Clinical findings in two patients with pathogenic variants in SPARC and literature review. J Med Genet 2022; 59:810.</li>
<li>Doyard M, Bacrot S, Huber C, et al. FAM46A mutations are responsible for autosomal recessive osteogenesis imperfecta. J Med Genet 2018; 55:278.</li>
<li>Lindert U, Cabral WA, Ausavarat S, et al. MBTPS2 mutations cause defective regulated intramembrane proteolysis in X-linked osteogenesis imperfecta. Nat Commun 2016; 7:11920.</li>
<li>Moosa S, Yamamoto GL, Garbes L, et al. Autosomal-recessive mutations in MESD cause osteogenesis imperfecta. Am J Hum Genet 2019; 105:836.</li>
<li>van Dijk FS, Semler O, Etich J, et al. Interaction between KDELR2 and HSP47 as a key determinant in osteogenesis imperfecta caused by bi-allelic variants in KDELR2. Am J Hum Genet 202; 107:989.</li>
<li>Dubail J, Brunelle P, Baujat G, et al. Homozygous loss-of-function mutations in CCDC134 are responsible for a severe form of osteogenesis imperfecta. J Bone Miner Res 2020; 35:1470.</li>
</ol>
<p class="extra_spacing_top">Data from:</p>
<ul>
<li>Steiner RD, Pepin MG, Byers PH. Osteogenesis imperfecta. GeneReviews at GeneTests: Medical Genetics Information Resource, January 2005.</li>
<li>Balasubramanian M. Clinical and Molecular Heterogeneity of Osteogenesis Imperfecta. Colloquium Series on Genomic and Molecular Medicine, Kumar D (Ed), Morgan &amp; Claypool Publishers 2017.</li>
</ul></div><div id="graphicVersion">Graphic 78737 Version 16.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
